Figure 6.
Analysis of cumulative survival of mice bearing Ramos lymphoma xenografts treated with PRIT using anti-CD20 B9E9 (scFv)4SA fusion protein and 1F5 Ab-SA chemical conjugate. Groups of 10 mice bearing Ramos tumor xenografts were treated as described in Figure 5 and analyzed for survival as a function of time. Treatment groups included mice treated with 1.4 nM of either B9E9 (scFv)4SA, control CC49 (scFv)4SA, or 1F5 Ab-SA, followed 20 hours later by 5.8 nM CA, and 4 hours after that with 200, 400, 800, 1000, or 1200 μCi (7.4, 14.8, 29.6, 37, or 44.4 MBq, respectively) 90Y-DOTA-biotin. Survival curves in this figure correspond to treatment groups designated in Figure 5.
